[1] |
LIN Jiaxin, WEI Ran, SHUI Ruohong, LU Hongfen, LI Xiaoqiu, YU Baohua.
Clinicopathological analysis of adrenal intravascular large B-cell lymphoma
[J]. China Oncology, 2024, 34(11): 1020-1027.
|
[2] |
WU Zhibai, XU Guiqin, ZHANG Li, YANG Zhaojuan, LIU Yun, JIAO Kun, CHEN Zehong, XU Chen, ZUO You, ZHENG Ningqian, YE Zhiqian, LIU Yongzhong.
Mechanism study of KCMF1 promoting proliferation and NF-κB signaling transduction in colorectal cancer cells
[J]. China Oncology, 2024, 34(11): 987-997.
|
[3] |
WEI Jing, HE Yaqi, XUE Tian, BAI Qianming, SHUI Ruohong, LU Hongfen, LI Xiaoqiu, YU Baohua.
Clinicopathological analysis of DLBCL/HGBL with MYC, BCL2 and BCL6 gene rearrangement
[J]. China Oncology, 2023, 33(9): 809-817.
|
[4] |
CHEN Hong, CHEN Junxia.
Effect of hsa_circ_0001573 on biological behaviors of breast cancer cells and its molecular mechanism
[J]. China Oncology, 2023, 33(4): 342-353.
|
[5] |
CD-Positive Lymphoma Pathology Expert Group.
The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas
[J]. China Oncology, 2023, 33(3): 228-234.
|
[6] |
HE Liyuan, WANG Yudong.
Research progress of ALK kinase domain drug resistance mutation and its future countermeasures
[J]. China Oncology, 2022, 32(8): 736-746.
|
[7] |
LIU Yanquan, HU Xiaomei, YIN Yue, LIN Lin, SHEN Jianzhen, CHEN Yuting, TANG Huanwen.
A retrospective study and clinical analysis of post-transplant lymphoproliferative disorder
[J]. China Oncology, 2022, 32(7): 650-656.
|
[8] |
LI Xiaoqiu, CD30 Positive Lymphoma Pathology Expert Group.
Detection of CD30 expression in lymphomas: status and challenges
[J]. China Oncology, 2022, 32(6): 512-518.
|
[9] |
Diao Xinfeng, Li Xinmao, Hou Liang, Wei Zhixuan.
YTHDF2 promotes progression of glioblastoma via inducing mRNA decay of IGFBP7 and activating PI3K/AKT signaling pathway
[J]. China Oncology, 2022, 32(3): 218-227.
|
[10] |
CHEN Guangliang, WU Fangtian, CAO Junning.
Advances in research on EBV positive diffuse large B-cell lymphoma, not otherwise specified
[J]. China Oncology, 2022, 32(3): 258-267.
|
[11] |
JIN Zhengming.
Clinical practice optimization exploration and future prospects of autologous hematopoietic stem cell transplantation for lymphoma
[J]. China Oncology, 2022, 32(2): 161-171.
|
[12] |
CAO Dalong, YE Dingwei.
New trends and future prospects of regulatory cell death in renal carcinoma
[J]. China Oncology, 2022, 32(10): 1000-1006.
|
[13] |
CHEN Yifan, SHEN Yihui, CHENG Leilei, LIN Jinyi, ZHANG Hui, WANG Xuejun, XU Yuchen, ZHANG Jian, GE Junbo.
Different preventive effects of four cardioprotective agents on mice with adriamycin-induced cardiotoxicity
[J]. China Oncology, 2022, 32(10): 936-947.
|
[14] |
LI Haizhou , ZHANG Yanwei , XU Yingjie , YANG Men , ZHANG Lei , HAN Jingjun .
miR-933 inhibits proliferation, migration and invasion of lung cancer cell lines by regulation of KLF6 gene
[J]. China Oncology, 2021, 31(7): 581-588.
|
[15] |
CAO Dalong, ZHU Wenkai, SHI Guohai, ZHANG Hailiang, WANG Ziliang, YE Dingwei.
The influence of PRUNE2 gene point mutation on proliferation, apoptosis, invasion and migration of prostate cancer DU145 cells
[J]. China Oncology, 2021, 31(6): 441-446.
|